Internationally renowned experts form independent Bayer Bioethics Council
Internationally renowned experts form independent Bayer Bioethics Council Bayer establishes Bioethics Council Experts from different academic disciplines to provide broad external perspective and guidance on complex bioethical questions related to…
Elisabeth Moreno to join Sanofi’s Diversity, Equity and Inclusion Board
Elisabeth Moreno to join Sanofi’s Diversity, Equity and Inclusion Board Sanofi announces the appointment of Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal opportunities, to its Diversity,…
Sanofi, AstraZeneca and Sobi simplify contractual agreements
Sanofi, AstraZeneca and Sobi simplify contractual agreements Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new…
Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. Sanofi announced today that it…
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Two studies, published in The Lancet and The…
Veklury®(Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being…
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies Bristol-Myers Squibb…
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma U.S. FDA accepted Bristol Myers Squibb and 2seventy…
Novo Nordisk raises sales and operating profit outlook for 2023
Novo Nordisk raises sales and operating profit outlook for 2023 Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months…
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement…
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing…
FDA approves Roche’s Policy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
FDA approves Roche’s Policy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the…